Nektar Therapeutics
NKTR
336 hedge funds and large institutions have $5.91B invested in Nektar Therapeutics in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 124 increasing their positions, 124 reducing their positions, and 40 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
8% more capital invested
Capital invested by funds: $5.48B → $5.91B (+$425M)
0.11% more ownership
Funds ownership: 6.24% → 6.36% (+0.11%)
0% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 124
4% less funds holding
Funds holding: 350 → 336 (-14)
18% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 40
49% less call options, than puts
Call options by funds: $35.1M | Put options by funds: $69.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$713M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$73.6M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$31.3M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
+$28.6M |
| 5 |
BlackRock
New York
|
+$25.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$59.3M |
| 2 |
D.E. Shaw & Co
New York
|
-$29.3M |
| 3 |
JP Morgan Chase
New York
|
-$22.5M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$15.9M |
| 5 |
Morgan Stanley
New York
|
-$12.3M |
NKTR Hedge Fund Activity: Q2 2019 in Review
336 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2019, worth a combined $5.91B — up 7.8% from $5.48B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of NKTR and 33 opened new positions — a net loss of 7 holders — while 124 trimmed existing stakes and 124 added.
The largest buyer was Invesco, adding an estimated $713M. The largest seller was Fidelity Investments, cutting an estimated $59.3M.
- 336 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2019, down from 350 in Q1 2019.
- Funds reported $5.91B of Nektar Therapeutics stock for Q2 2019, up 7.8% quarter-over-quarter.
- 33 funds opened new Nektar Therapeutics positions in Q2 2019 and 40 closed out, a net change of -7 holders.
- The largest Nektar Therapeutics buyer in Q2 2019 was Invesco, an estimated $713M added.
- The largest Nektar Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $59.3M sold.
Based on aggregated 13F filings for Q2 2019.